The drug lenvatinib can significantly improve overall survival rates in a group of thyroid cancer patients whose disease is resistant to standard radioiodine treatment, according to new research from the Perelman School of Medicine at the University of Pennsylvania. (sciencedaily.com)
Up to 44 percent of papillary thyroid cancer patients have a B - raf mutation that can be specifically targeted by existing cancer drugs. (sciencedaily.com)
«Drug targeting BRAF mutation slows thyroid cancer, too: Vemurafenib elicits a response in a third of advanced thyroid cancer patients with the BRAFV600E mutation.» (sciencedaily.com)